Document is current
Any future updates will be listed below
-
Authors
Soucy, Megan
Kolesnikova, Masha
Kim, Angela H.
Tsang, Stephen H. https://orcid.org/0000-0001-9082-2427
-
Funding
Funding for this research was provided by:
NIH Clinical Center (R01EY09076)
NIH Clinical Center (5P30CA013696)
NIH Clinical Center (U01 EY030580)
NIH Clinical Center (U54OD020351)
NIH Clinical Center (R24EY028758)
NIH Clinical Center (R24EY027285)
NIH Clinical Center (5P30EY019007)
NIH Clinical Center (R01EY018213)
NIH Clinical Center (R01EY024698)
NIH Clinical Center (R01EY026682)
NIH Clinical Center (R21AG050437)
Foundation Fighting Blindness (TA-NMT-0116-0692-COLU)
New York Stem Cell Foundation (SDHDOH01-C32590GG-3450000)
- License Information
-
More Information
Article History
Received: 25 May 2022
Accepted: 14 December 2022
First Online: 7 January 2023
Declarations
:
: Stephen H. Tsang receives financial support from Abeona Therapeutics, Inc. and Emendo. He is also the founder of Rejuvitas and is on the scientific and clinical advisory board for Nanoscope Therapeutics and Medical Excellence Capital. Megan Soucy, Masha Kolesnikova, and Angela H Kim have no conflicts of interest to report.
: No animals were used in this study.
